The poster presentation was given by Dr. Joshua Tobias at the American Association of Cancer Research (AACR) Annual Meeting (April 5-10, 2024; San Diego, CA, USA). Dr. Sharon Yavrom (in the Photo), a representative from the cooperation partner company Imugene Ltd, which has coordinated the Phase Ib and Phase II trial of HER-Vaxx, was also at the poster session.
A manuscript on the significant HER-Vaxx Phase II final results showing the vaccine's safety profile, clinical efficacy in terms of overall survival, progression-free survival, and tumor reduction, which significantly correlated with vaccine-induced immune responses, has now been published (Tobias et al, Clin. Cancer Res. 2024, 30:4044–4054; https://doi.org/10.1158/1078-0432.CCR-24-0742).